内科学
心脏病学
肺动脉
波生坦
曲前列环素
血压
作者
Bradley A. Maron,Steven H. Abman,C. Greg Elliott,Robert P. Frantz,Rachel K. Hopper,Evelyn M. Horn,Mark R. Nicolls,Oksana A. Shlobin,Sanjiv J. Shah,Gabor Kovacs,Horst Olschewski,Erika B. Rosenzweig
标识
DOI:10.1164/rccm.202012-4317so
摘要
The diagnosis and management of pulmonary arterial hypertension (PAH) includes several advances, such as a broader recognition of extrapulmonary vascular organ system involvement, validated point-of-care clinical assessment tools, and focus on the early initiation of multiple pharmacotherapeutics in appropriate patients. Indeed, a principal goal in PAH today is an early diagnosis for prompt initiation of treatment to achieve a minimal symptom burden; optimize the patient's biochemical, hemodynamic, and functional profile; and limit adverse events. To accomplish this end, clinicians must be familiar with novel risk factors and the revised hemodynamic definition for PAH. Fresh insights into the role of developmental biology (i.e., perinatal health) may also be useful for predicting incident PAH in early adulthood. Emergent or underused approaches to PAH management include a novel TGF-β ligand trap pharmacotherapy, remote pulmonary arterial pressure monitoring, next-generation imaging using inert gas-based magnetic resonance and other technologies, right atrial pacing, and pulmonary arterial denervation. These and other PAH state of the art advances are summarized here for the wider pulmonary medicine community.
科研通智能强力驱动
Strongly Powered by AbleSci AI